

GPR3 Ligands Discovered through Combined Virtual and Conformational Biosensor-Based Screening

Hannes Schihada,* Aida Shahraki,[○] Ainoleena Turku-Metsänen,[○] Maximilian Rath, Lukas Wirth, Katarina Nemec, Hrisowalantu Tselepli, Laura Heitzer, Bernadette Vallaster, Mariam Fadel, Gunnar Schulte, Daniel Hilger, Steffen Pockes, Martin J. Lohse,* and Peter Kolb*



Cite This: *J. Am. Chem. Soc.* 2026, 148, 20285–20295



Read Online

ACCESS |



Metrics & More




Article Recommendations



Supporting Information

ABSTRACT: GPR3 belongs to the protein superfamily of G protein-coupled receptors (GPCRs) and plays a central role in both benign and malignant physiological processes, such as energy expenditure in adipocytes and Alzheimer's disease pathology, respectively. Despite the therapeutic potential of both receptor agonists and inverse agonists, GPR3 so far has lacked drug-like ligands and innovative screening technologies, hindering effective drug discovery efforts targeting this receptor. To overcome the limitations of conventional ligand screening techniques based on cAMP accumulation or β -arrestin recruitment, we developed a conformational GPR3 biosensor to monitor receptor activity in living cells with high-throughput screening (HTS)-compatible sensitivity and robustness. Combined with virtual compound screening against homology models of GPR3 and classical medicinal chemistry, this biosensor enabled us to identify new ligands, one of which (compound 33) modulates GPR3-dependent G_i activity with an average potency in the nanomolar range. Our study not only presents novel GPR3 ligands for future optimization efforts and paves the way for even further expansion of the GPR3 ligand repertoire, but our sensor approach also provides a blueprint for targeting other therapeutically attractive yet challenging orphan GPCRs.



INTRODUCTION

Members of the protein superfamily of G protein-coupled receptors (GPCRs) are targeted by more than 30% of FDA-approved drugs. However, more than two-thirds of all nonfactory GPCRs remain untapped for disease therapy, including many orphan GPCRs—receptors with yet unknown endogenous ligands. While one of the class A orphan GPCRs, GPR3, has only recently been deorphanized,^{1–3} it still lacks drug-like ligands; moreover, innovative technologies to better study this receptor are just beginning to emerge.⁴

GPR3, together with GPR6 and GPR12, is phylogenetically related to receptors that bind sphingosine-1-phosphate (S1P), lysophosphatidic acid (LPA), cannabinoids and proopiomelanocortin-derived peptides. GPR3 activity is involved in both benign and malignant physiological processes. In the central nervous system (CNS), GPR3 mediates neurite outgrowth and neuronal cell survival^{5,6} but has also been implicated in Alzheimer's disease.^{7–10} In the periphery, GPR3 regulates oocyte maturation and drives thermogenic programs in adipocytes.¹¹ These examples demonstrate that both agonists and inverse agonists of GPR3 may be of therapeutic value for various pathologies. Although researchers have been trying to discover molecules that target GPR3 for more than two decades, only a limited set of ligands that were validated in independent laboratories is currently available (Chart 1).

While the activity of S1P and cannabidiol (CBD) on GPR3 remains questionable,^{12–16} AF64394 and its structural analogs have demonstrated their value as GPR3-specific inverse agonists.^{4,17,18} In addition, diphenyleneiodonium chloride (DPI) is a proven synthetic agonist of GPR3 and a DPI derivative promotes GPR3-dependent cAMP production with submicromolar potency.^{12,19} Furthermore, the recent biochemical and structural studies revealed that endogenous long-chain lipids and fatty acids stabilize GPR3 in an active conformation.^{1,2}

The limited number of success stories illustrates that today's GPR3-targeted drug discovery is hampered by a poor understanding of the role of this receptor in cellular signaling and by a limited panel of assays that reveal GPR3 activity in living cells. This is emphasized by the fact that the few GPR3 ligands currently validated were discovered using one of only two available assay principles—cAMP accumulation or β -arrestin recruitment.^{12,17,18} Both assays detect selected cellular

Received: April 1, 2026


Revised: April 23, 2026

Accepted: April 28, 2026

Published: May 7, 2026



Chart 1. Structures of Proposed GPR3 Ligands



functions of GPR3 but may not represent the full repertoire of GPR3-mediated events in cells. These readouts are therefore limited in detecting GPR3-targeting compounds and we reasoned that an innovative sensing approach is needed to facilitate tailored GPR3 ligand screening with higher success rates. We aimed to develop a sensor that detects compound-induced changes in GPR3 activity in a pathway-independent manner in a medium- to high-throughput screening (HTS) assay format. The latest generation of conformational GPCR sensors, based on bioluminescence resonance energy transfer (BRET) between NanoLuciferase (Nluc)²⁰ and HaloTag,²¹ fulfills these criteria.^{22–24}

Here, we present the generation of the first conformational biosensor for an orphan GPCR with HTS-compatible sensitivity and robustness. We further demonstrate how this optical tool enabled us to identify new GPR3 ligands by combining virtual compound screening against 3D receptor models with a classical medicinal chemistry approach. Our most potent new GPR3 ligand is an inverse agonist that induces conformational changes in GPR3 with low micromolar potency and reduced basal G_s activity downstream of GPR3 with an average potency in the nanomolar range.

RESULTS AND DISCUSSION

Design and Validation of a Conformational GPR3 Sensor

To develop a conformational GPR3 biosensor that can be used in a microtiter well plate format, we employed the intramolecular BRET design previously validated for several GPCRs.^{22–24} The BRET donor NanoLuc was fused to the receptor's full-length C-terminus and the self-labeling protein tag, HaloTag, was inserted into GPR3's third intracellular loop between amino acids Arg231 and His232 (Figure 1a; sequence in Figure S1). This GPR3-HaloTag/Nluc fusion construct even showed enhanced surface expression levels compared to wildtype GPR3, confirmed by whole-cell ELISA using the N-terminal HA-Tag of these GPR3 constructs (Figure 1b). Upon

expression of GPR3-HaloTag/Nluc in human embryonic kidney 293A cells (HEK293A), fluorescence labeling with the HaloTag NanoBRET 618 ligand and addition of Nluc substrate furimazine, BRET in the receptor's basal conformation was indicated in the luminescence emission spectrum by the characteristic acceptor peak around 620 nm (Figure 1c). In addition, treatment with the GPR3 inverse agonist AF64394 resulted in a time- and ligand-concentration-dependent increase in BRET (Figure 1d,e). The EC_{50} value of 161 nM is similar to the affinity of AF64394 for N-terminally Nluc-fused GPR3⁴ and to its potency in a GPR3 wildtype-dependent cAMP assay,¹⁷ demonstrating the functionality of this conformational GPR3 biosensor. Additionally, experiments with a GPR3-HaloTag/Nluc mutant with impaired AF64394 binding⁴ (Figure 1e) and with HaloTag/Nluc-based biosensors of the α_2A - and β_2 -adrenergic receptors (β_2AR)²² confirmed the specificity of the AF64394-induced GPR3 biosensor response (Figure S2). In contrast to the inverse agonist AF64394, the endogenous agonists OEA and oleamide induced concentration-dependent decreases in BRET (Figure 1f), confirming that the biosensor reports ligand efficacy. To assess the suitability of this new sensor for medium- to high-throughput ligand screening, we measured its Z' -factor²⁵ in four independent experiments, confirming the high sensitivity (mean $\pm$ SEM Z' -factor = 0.78 ± 0.02) and low interday variability (coefficient of variation = 6.3%) (Figures 1g and S3). Ultimately, we confirmed the signaling capacity of the GPR3 sensor using a cAMP biosensor²⁶ (Figure 1h). These experiments revealed elevated basal levels of cAMP when GPR3-HaloTag/Nluc was coexpressed (Figure 1i) and a concentration-dependent reduction of cAMP by AF64394 (Figure 1j), demonstrating that the GPR3 conformational biosensor has wildtype-like signaling capacity.

Virtual Screening for New GPR3 Ligands

To demonstrate the value of this signaling pathway-independent readout of receptor activity for ligand discovery




Figure 1. Development of a conformational GPR3 biosensor. (a) Design and principle of the conformational GPR3 biosensor. (b) Surface expression of wildtype GPR3 and the GPR3 biosensor. (c) Luminescence spectra of the HaloTag labeled and unlabeled GPR3 sensor. (d) AF64394-induced Δ BRET time course of the GPR3 biosensor. (e, f) Concentration–response curves of AF64394 (e) or OEA and oleamide (f) obtained with the GPR3 sensor or a mutant variant. (g) Z-factor of the GPR3 biosensor. (h) Scheme of the cAMP assay to assess the signaling capacity of the GPR3 biosensor. (i) cAMP sensor BRET ratio upon coexpression of GPR3 sensor or wildtype. (j) Concentration–response curves of AF64394 obtained with the cAMP biosensor in cells cotransfected with pcDNA, GPR3 wildtype or GPR3 sensor. All experiments were conducted in transiently (b–e, h), (i) or stably (f) expressing HEK293A cells. Data show the mean $\pm$ SEM of three to five independent experiments. Statistical significance in (b) and (h) was tested using One-Way ANOVA followed by Tukey's multiple comparison. Statistical difference of $\log EC_{50}$ values in (e) and between the top plateaus in (i) was tested using the extra-sum-of-squares F-test. *: $p < 0.05$; ***: $p = 0.0002$; ****: $p < 0.0001$.

campaigns, we used the conformational biosensor to screen for GPR3 activity modulating compounds. To preselect the compounds to be tested *in vitro*, we conducted a structure-based *in silico* screening using molecular docking calculations.²⁷ At the time this study started, no experimental structures of GPR3 or the related receptors GPR6 and GPR12 were available. Hence, we constructed active- and inactive-state GPR3 homology models based on experimental structures of the phylogenetically related cannabinoid receptor 1 (PDB IDs 6N4B and 5TGZ, respectively) (Figure S4a–c). In exploratory docking calculations against the orthosteric pockets of both GPR3 models to assess their utility in a prospective screening, AF64394 and two structural analogs were ranked favorably compared to a randomly selected subset of our virtual

compound library (about 700 molecules), indicating that the models were indeed able to recognize these GPR3 ligands (Figure S4d,e). While encouraging, a recent experimental structure of GPR3 in complex with AF64394 shows that this ligand does not bind to the orthosteric pocket³¹, hence we would not have included this step had the project been started today. A library of around 70,000 readily available compounds from the Chemical Biology Consortium Sweden (CBCS) was then docked to each of these structures (about 110,000 entries at pH 7 ± 2). The docking poses of the top 100 (based on the docking score) molecules were visually inspected for each of the docking calculations to the active- and inactive-state GPR3 models. Additionally, the poses of 120 molecules from a consensus list (between the top 1000 molecules of either




Figure 2. *In vitro* testing of virtual screening hits. (a) BRET changes of GPR3-HaloTag(618)/Nluc induced by 93 test compounds (1 μ M), vehicle control (gray) or 10 μ M AF64394 (red, positive control). The gray shaded area indicates negative control $\pm$ 3-fold SD. Blue data points represent the screening hits VH1, VH2 and VH3. (b–d) Concentration response curves of in-house synthesized rac-VH1/52, VH2/93 and VH3/115 obtained with the GPR3- or β_2 AR-HaloTag(618)/Nluc sensor. Data show mean $\pm$ SEM of two (a) or three (b–d) independent experiments conducted in HEK293A cells stably expressing the biosensors.

docking calculation) were evaluated. After this visual inspection followed a clustering of compounds based on 2D similarity to obtain a high structural diversity of compounds to be tested. Finally, 31 and 20 molecules were obtained from the lists resulting from docking to both GPR3 models and 42 compounds were obtained from the consensus list for *in vitro* testing.


In Vitro Testing of Virtual Hits

Initially, all 93 molecules were tested for activity at the GPR3 biosensor at a concentration of 1 μ M (Figure 2a). Only three compounds induced a BRET response exceeding the threshold of the mean vehicle response $\pm$ 3-fold standard deviation and were subsequently applied at serial dilutions to cells expressing either GPR3- or β_2 AR-HaloTag/Nluc²² (Figure S5a–c). All three compounds induced GPR3-specific conformational changes. We hence searched for commercially available derivatives of these three molecules and obtained 14 additional compounds. Among these analogs, two more compounds induced GPR3-specific conformational changes (Figure S5d–f). Of the five compounds that emerged from the virtual screen, three—hereafter referred to as virtual hit 1–3, VH1/2/3—were selected for in-house chemical synthesis (compounds 52, 93, and 115; cf. Scheme 1, Figure S6), providing compounds of $\geq$ 99% purity for hit validation (NMR spectra: Figures S7–S142; HPLC purity: Figures S143–S218). For

VH1, the racemic mix, rac-VH1/52, was synthesized and used for testing. Compounds 52, VH2/93, and VH3/115 (Figure S6) were then validated with the GPR3 biosensor including β_2 AR-HaloTag/Nluc as a negative control. All three compounds induced concentration-dependent and GPR3-specific conformational changes with potencies ranging from 25 (rac-VH1) to 85 μ M (VH3) (Figure 2b–d).

With the first GPR3 ligands identified by using a conformational readout in our hands, we next wanted to understand whether these compounds could have been detected in a cAMP-based assay, which has been used extensively in the past to screen for GPR3 ligands. We therefore tested rac-VH1/52, VH2/93 and VH3/115 in cells expressing a cAMP biosensor. Interestingly, only rac-VH1 and—to a much lesser extent—VH2 induced GPR3-dependent changes in cAMP concentrations, demonstrating that a cAMP-based screen would likely have incorrectly classified VH3 as inactive (Figure 3).

Unfortunately, the GPR3-HaloTag/Nluc responses observed with 10 and 100 μ M compound treatment suggested that none of the 18 further VH1/2/3-related molecules (c.f. SI for selection) were significantly more potent than the template molecules (Figures S219–S221). Hence, we decided to take this information and used classical medicinal chemistry strategies to derivatize VH1/VH2/VH3 in smaller increments and obtain analogs more similar to the templates (Figure

Scheme 1. Synthesis of VH1-3 Analogs 21–37 (A), 52–77 (B, C), 80–84 (D), 93–110 (E), 115–124 (F)^a

^aReagents and conditions: (a) *N*-bromosuccinimide (1.2 equiv), PPh₃ (1.2 equiv), DCM, 4 h, 0 °C; (b) butan-2-one, 48 h, 90 °C; (c) 20 M NaOH, acetone, 2 h, 60 °C; (d) EtOH, 48 h, 100 °C; (e) CH₃I (1.2 eq), K₂CO₃ (3.0 equiv), DMF, overnight, rt; (f) LiAlH₄ (2.0 equiv), TFA, 4 d,

Scheme 1. continued

0 °C to rt; (g) methanesulfonyl chloride (2.0 equiv), TEA (2.0 equiv), DCM, overnight, 0 °C to rt; (h) sodium salt (3 equiv), DMF, overnight, 110 °C; (i) 20% TFA in DCM, overnight, 0 °C to rt; (k) bicyclic carboxylic acid (2.0 eq), DIPEA (3 equiv), HATU (1.1 eq), DMF, overnight, rt; (l) 4-methylaniline (1 equiv), TEA (2 equiv), DCM, 4–6 h, 0 °C to rt; (m) *tert*-butyl-piperazine-1-carboxylate (3 equiv), K₂CO₃ (5.0 equiv), CH₃CN, 5 h, 80 °C; (n) 50% TFA in DCM, 3 h, rt; (o) 3-phenylpropanoic acid derivative (1 eq), DIPEA (2–3 equiv), HATU (1.2–1.5 eq), TEA (2 eq), DCM, 12 h, –15 °C.




Figure 3. Effect of rac-VH1/52, VH2/93 and VH3/115 on GPR3-dependent cAMP production. (a–c) Vehicle-corrected BRET changes induced by rac-VH1/52 (a), VH2/93 (b) or VH3/115 (c) in HEK293A cells transiently transfected with a cAMP BRET sensor along with pcDNA or GPR3. Data show mean $\pm$ SEM of three independent experiments. Statistical significance was tested using Two-Way ANOVA followed by Sidak multiple comparison (*: $p < 0.5$; **: $p < 0.01$).

S222). In total, we synthesized 48 different analogs of VH1 (21–37, 52–77, and 80–84; including rac-VH1/52), 17 VH2 analogs (93–110) and 9 VH3 analogs (115–124) (cf. Scheme 1) with modifications in different regions of the molecule. Details regarding the synthesis and analytical validation of these molecules can be found in the Supporting Information (NMR spectra: Figures S7–S142; HPLC purity: Figures S143–S218) and Scheme 1. All 74 rac-VH1/VH2/VH3 analogs were first tested at two different concentrations, 10 μ M and 100 μ M, with GPR3-HaloTag(618)/Nluc and the observed BRET changes were compared to those obtained with VH1/2/3 in the same biological replicates (Figures 4a and S223). From these results, promising analogs were selected for full concentration–response experiments at GPR3-HaloTag(618)/Nluc. Three interesting VH1 derivatives emerged from this analysis: While compounds 56 and 80 showed only small left-shifts of the concentration–response curves (i.e., higher potency) compared to the template molecule rac-VH1/52 (Figure 4b,c), 33 showed a more pronounced, approximately 6-fold, improvement in ligand potency (Figure 4d) and selectivity for GPR3 over β_2 AR (Figure 4e). Structurally, 33 shares very little similarity with the known GPR3 inverse agonist AF64394 (atom pair Tanimoto = 0.22; maximum common substructure Tanimoto = 0.20 using PubChem fingerprints as implemented on chemminetools.ucr.edu²⁸), underscoring the novelty of this compound as a GPR3 ligand.

The EC₅₀ value of 33 at the GPR3 conformational biosensor was 5 μ M (95% CI: 1–19 μ M). Strikingly, 33 showed a reduced amplitude in the GPR3 conformational change readout (which was still robustly reproducible in all of our independent experiments; Figure S224), indicating that the modification from rac-VH1/52 to 33 caused a loss in inverse agonist efficacy while enhancing ligand affinity. To obtain deeper insights into the structure–activity relationship of rac-

VH1/52 and 33, we further collected concentration–response data for other VH1 derivatives of this analog series (Figure 4f,g). Our analysis revealed that the hydroxy and ether-groups, as well as the *para* chlorine substituent are dispensable for VH1 action because both 21 and 23 showed similar efficacy as rac-VH1/52. In addition, the reduced BRET response obtained with 26 and 27 indicates that the loss in inverse agonist activity for 33 could be due to the shortening of the linker between the central heterocyclic system and the “upper” aromatic ring (Figure 4f). This effect of side chain truncation was, however, strictly dependent on the cyclopropyl substituent, because none of the other truncated, saturated VH1 analogs (34–37) exhibited the low micromolar potency observed with 33 (Figure 4g).

To develop a hypothesis for the cause of the significant loss in efficacy from VH1 to 33, we computationally predicted the binding poses of both molecules in GPR3 (Figure 5a). Our docking suggests that the *para*-substituted phenyl ring of VH1 and its linker extend toward the extracellular space without making any contacts with the receptor. In contrast, the cyclopropyl ring of 33 is still buried in the receptor’s transmembrane core. Additionally, further energy minimization of the GPR3 ligands revealed that compound 33, but not VH1, can adopt an energetically favorable binding pose that is oriented closer toward transmembrane helix 2 (Figure S225). Notably, these computationally predicted poses of VH1 and 33 were supported by experimental data with mutant variants of the GPR3 showing wildtype-like surface expression levels.⁴ While the insertion of bulky tryptophan residues in extracellular loop 2 right-shifted the rac-VH1/52 concentration–response at the GPR3 biosensor (Figure 5b), 33 was not affected by these modifications (Figure 5c). We also challenged this binding model of 33 with another GPR3 biosensor variant which harbors the T^{3.37}A point mutation in transmembrane helix 3. According to an alternative predicted pose of 33 obtained with Boltz-2 (c.f., SI – Materials and Methods section), this mutation should hamper 33 binding to GPR3. However, our experiments with wildtype and mutant GPR3 biosensor showed no such effect on 33 activity (Figure S226). Taken together, these results support the binding pose depicted in Figure 5 and suggest that 33 binds to GPR3 in a different manner compared to VH1, which may relate to the mechanistic basis for the apparent reduction in inverse agonist efficacy from VH1 to 33.

Pharmacological Characterization of 33

To further delineate the pharmacological properties of 33, we evaluated its activity in signaling assays downstream of GPR3. When 33 was applied to HEK293A cells expressing our G_s dissociation biosensor, Gs-CASE,²⁹ a concentration- and GPR3-dependent increase in BRET was observed with an EC₅₀ value of 250 nM (95% CI: 13 nM–3 μ M) (Figure 6a,b). These data confirm that 33 is an inverse agonist of GPR3. We also investigated whether 33 blocks the activity of previously validated GPR3 ligands—the agonist DPI and the inverse




Figure 4. *In vitro* testing of VH1 analogs. (a) BRET changes of GPR3-HaloTag(618)/Nluc induced by vehicle control, rac-VH1/52 and 49 chemical analogs. (b–d) Concentration response curves of VH1 analogs 80 (b), 56 (c) and 33 (d) obtained with the GPR3-HaloTag(618)/Nluc sensor. (e) Comparison of the 33 response at GPR3- vs β_2 AR-HaloTag(618)/Nluc sensor. (f, g) Concentration response curves of rac-VH1/52 and its analogs 21, 23, 26, 27, 33, and 34–37 obtained with the GPR3-HaloTag(618)/Nluc sensor. Data show mean $\pm$ SEM of three independent experiments conducted in HEK293A cells stably expressing the indicated biosensor.

agonist AF64394 (Chart 1)—in a cAMP assay.³⁰ Intriguingly, 33 had no effect on the effect of AF64394 (Figure 6c), which is consistent with a recent experimental GPR3 structure showing nonorthosteric binding of AF64394³¹ but inhibited DPI-induced cAMP generation (Figure 6d). These data support our previous observation that DPI and AF64394 engage distinct sites in GPR3⁴ and suggest that 33 competes with DPI for GPR3 binding. Additionally, we observed reduced potency of OEA, but not oleamide, in the GPR3 conformation assay following preincubation with 33 (Figure S227). The differential effect between OEA and oleamide may reflect differences in their conformational and/or positional flexibility within the GPR3 binding pocket. This difference is supported by MD

simulations of oleamide in GPR3¹ and by a comparison of oleic acid binding poses in the highly similar pockets of GPR3 and GPR6.^{2,32}

Next, we used the classical cAMP GloSensor technology to assess the target selectivity profile of 33. Addition of 33 to the constitutively G_s -coupled receptors GPR6 and GPR12—the closest phylogenetic relatives of GPR3—revealed no receptor-specific changes in cAMP levels below 100 μ M 33, while a concentration-dependent decrease in cAMP was observed in GPR3-expressing cells with an EC_{50} value of 2 μ M (95% CI: 0.2–17 μ M; Figure 6e). In addition, we tested the effects of 33 on cAMP changes mediated by agonist-stimulated GPCRs phylogenetically close to GPR3 and coupling to G_s or $G_{i/o}$




Figure 5. Proposed binding poses of VH1 and 33. (a, b) Computationally predicted binding poses of VH1 (a) and 33 (b) in GPR3 (model based on PDB 8X2K). (c, d) Concentration response curves of rac-VH1/52 (c) and 33 (d) obtained with wildtype and mutant GPR3 conformational sensors. Data show the mean $\pm$ SEM of three independent experiments conducted in transiently transfected HEK293A cells. Statistical difference of the pEC_{50} values was tested using extra-sum-of-squares F-test (* $p < 0.05$).

proteins. Preincubation with neither 100 μ M nor 10 μ M 33 significantly altered the agonist-induced cAMP change mediated by the adenosine A_{2B} receptor ($A_{2B}R$), the cannabinoid receptor 1 (CB_1R), the S1P receptor 1 ($S1PR1$) or the LPA receptor 1 ($LPAR1$) (Figure S228). In summary, these data imply that 33 is selective for GPR3 among the seven receptors included in this selectivity profiling.

Physicochemical Properties of 33

Finally, we assessed the physicochemical properties of 33 using the SwissADME Swiss Drug Design online tool.³³ This analysis indicated that 33, with a molecular weight of only 277 g/mol, a calculated Log-P of 2.9, no Lipinski rule violations, zero PAINS alerts, high leadlikeness and high synthetic accessibility (2.4 on a scale ranging from 1–10/highly accessible-not accessible), provides ample room for synthetic expansions and modifications in future campaigns aiming for more potent and efficacious 33 analogs.

CONCLUSIONS

GPR3 is a class A GPCR that holds great potential for the development of treatments against severe human diseases. However, the therapeutic exploitation of this target is hampered by a very limited number of available GPR3 ligands. To fill this gap, we have developed an analytical tool that enables the discovery and characterization of new GPR3 ligands. Our biosensor detects ligand-induced conformational changes in GPR3 and allowed us to identify and optimize new ligands by combining this advanced analytical tool with virtual compound screening and classical medicinal chemistry. Our virtual screening approach based on compound docking to 3D

models of GPR3 revealed three chemically novel inverse agonists of GPR3, VH1–3. Subsequent synthesis of more than 70 VH1/2/3 analogs allowed us to further improve the potency of VH1 and identify one of its chemical analogs, 33, as a GPR3 ligand with low micromolar potency in the conformational readout ($EC_{50} = 5 \mu$ M) and submicromolar potency in a signaling-based G protein reassociation assay ($EC_{50} = 249$ nM). Additionally, mutagenesis studies and competition experiments with two known GPR3 ligands provided insights into the binding mode of 33 at GPR3. In the future, 33 may, due to its favorable chemical characteristics, serve as a useful lead structure for the development of advanced GPR3 inverse agonists that could aid in the treatment of severe, GPR3-dependent diseases such as Alzheimer's disease. Its low molecular weight, balanced physicochemical properties and high synthetic accessibility allows for extensive chemical derivatization toward further advanced GPR3 inverse agonists.

Collectively, our results demonstrate the power of structure-based ligand discovery pipelines including readily applicable conformational GPCR biosensors. Using such tools, the modulation of receptor activity can be detected in a downstream signaling pathway-independent—and therefore unbiased—manner, reducing the risk of false screening results. This advantage is particularly relevant for poorly studied targets, e.g., orphan GPCRs with often unknown signaling patterns, as exemplified by the discovery of VH3/115. VH3/115 modulates the conformation of GPR3 but not GPR3-dependent cAMP production. This provides evidence for an unproductive GPR3 conformation that is stabilized by VH3 or GPR3 signaling via G_s - and cAMP-independent pathways, possibilities that require further investigation.

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/jacs.6c06780>.

Source information and SMILES for all compounds (XLSX)

Materials and methods section, amino acid sequence of the GPR3 biosensor, supporting experimental data, GPR3 homology model snapshots and validation data, and chemical synthesis information supplemented with the analytical data of new compounds (PDF)

AUTHOR INFORMATION

Corresponding Authors

Hannes Schihada – Philipps-Universität Marburg, Institute of Pharmaceutical Chemistry, 35032 Marburg, Germany;

orcid.org/0000-0002-1889-1636; Email: schihada@uni-marburg.de

Martin J. Lohse – ISAR Bioscience Institute, 82152 Munich, Germany; TU München Klinikum Rechts der Isar, 81675 Munich, Germany; Rudolf-Boehm-Institute for Pharmacology and Toxicology, Faculty of Medicine, Leipzig University, 04107 Leipzig, Germany; Email: martin.lohse@isarbioscience.de

Peter Kolb – Philipps-Universität Marburg, Institute of Pharmaceutical Chemistry, 35032 Marburg, Germany;

orcid.org/0000-0003-4089-614X; Email: peter.kolb@uni-marburg.de




Figure 6. Pharmacological characterization of compound 33. (a) Schematic of a live-cell G_s heterotrimer dissociation/reassociation assay to assess GPR3-dependent G_s activity. (b) Concentration response curves of 33 obtained with the G_s dissociation sensor in cells cotransfected with GPR3 or empty vector control (pcDNA). (c, d) Concentration response curves of AF64394 (c) and DPI (d) obtained with a cAMP biosensor in cells coexpressing GPR3 and pretreated with 30 μ M 33 or vehicle control. (e) Concentration response curves of 33 obtained with the cAMP GloSensor in cells cotransfected with GPR3, GPR6, GPR12 or empty vector control (pcDNA). Data show mean $\pm$ SEM of three (c–e) or four (b) independent experiments conducted in HEK293A cells transiently expressing the indicated proteins.

Authors

Aida Shahraki – Philipps-Universität Marburg, Institute of Pharmaceutical Chemistry, 35032 Marburg, Germany
Ainoleena Turku-Metsänen – Section of Receptor Biology & Signaling, Department of Physiology and Pharmacology, Karolinska Institutet, 17177 Stockholm, Sweden; Present Address: Orion Pharma R&D, Orionintie 1A, Espoo 02101, Finland; orcid.org/0000-0003-0959-7221
Maximilian Rath – Institute of Pharmacy, University of Regensburg, 93053 Regensburg, Germany
Lukas Wirth – Institute of Pharmacy, University of Regensburg, 93053 Regensburg, Germany
Katarina Nemec – Max Delbrück Center for Molecular Medicine in the Helmholtz Association, 13125 Berlin, Germany; Present Address: St. Jude Children's Research Hospital, Memphis, Tennessee 38105, United States
Hrisowalantu Tselepli – Institute of Pharmacy, University of Regensburg, 93053 Regensburg, Germany
Laura Heitzer – Institute of Pharmacy, University of Regensburg, 93053 Regensburg, Germany
Bernadette Vallaster – Institute of Pharmacy, University of Regensburg, 93053 Regensburg, Germany
Mariam Fadel – Philipps-Universität Marburg, Institute of Pharmaceutical Chemistry, 35032 Marburg, Germany; orcid.org/0000-0001-8441-9623
Gunnar Schulte – Section of Receptor Biology & Signaling, Department of Physiology and Pharmacology, Karolinska Institutet, 17177 Stockholm, Sweden; orcid.org/0000-0002-2700-7013
Daniel Hilger – Philipps-Universität Marburg, Institute of Pharmaceutical Chemistry, 35032 Marburg, Germany

Steffen Pockes – Institute of Pharmacy, University of Regensburg, 93053 Regensburg, Germany

Complete contact information is available at:
<https://pubs.acs.org/10.1021/jacs.6c06780>

Author Contributions

○A.S. and A.T.-M. contributed equally to this work. The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.

Funding

This project has received funding from the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No. 101062195. P.K. thanks the German Research Foundation DFG for Heisenberg professorships KO4095/4–1 and KO4095/5–1. S.P. thanks the German Research Foundation DFG for Heisenberg professorship PO2563/4–1 and research grant PO2563/5–1. The work at Karolinska Institutet was supported by the German Research Foundation DFG (427840891) and the Swedish Research Council (2019–01190).

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

The authors thank Anna Krook at the Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden, for providing access to the ClarioStar plate

reader; Ulrike Zabel at the Institute of Pharmacology and Toxicology, University of Wuerzburg, Germany, for cloning support; Alexander Roth at the Department of Pharmacy, Marburg University, for support in setting up the BOLTZ2.0 calculations; and Sigurd Elz for providing the infrastructure at the University of Regensburg. M.J.L. and K.N. were supported by the SFB1423.

■ ABBREVIATIONS

β_2 AR, β_2 -adrenergic receptors; BRET, bioluminescence resonance energy transfer; CBD, cannabidiol; CNS, central nervous system; DPI, diphenyleneiodonium chloride; FRET, fluorescence resonance energy transfer; GPCR, G protein-coupled receptor; HEK293, human embryonic kidney; LPA, lysophosphatidic acid; Nluc, Nanoluciferase; S1P, sphingosine-1-phosphate (S1P)

■ REFERENCES

- (1) Chen, G.; Staffen, N.; Wu, Z.; Xu, X.; Pan, J.; Inoue, A.; Shi, T.; Gmeiner, P.; Du, Y.; Xu, J. Structural and Functional Characterization of the Endogenous Agonist for Orphan Receptor GPR3. *Cell Res.* **2024**, *34* (3), 262–265.
- (2) Xiong, Y.; Xu, Z.; Li, X.; Wang, Y.; Zhao, J.; Wang, N.; Duan, Y.; Xia, R.; Han, Z.; Qian, Y.; Liang, J.; Zhang, A.; Guo, C.; Inoue, A.; Xia, Y.; Chen, Z.; He, Y. Identification of Oleic Acid as an Endogenous Ligand of GPR3. *Cell Res.* **2024**, *34* (3), 232–244.
- (3) Russell, I. C.; Zhang, X.; Bumbak, F.; McNeill, S. M.; Josephs, T. M.; Leeming, M. G.; Christopoulos, G.; Venugopal, H.; Flocco, M. M.; Sexton, P. M.; Wootten, D.; Belousoff, M. J. Lipid-Dependent Activation of the Orphan G Protein-Coupled Receptor, GPR3. *Biochemistry* **2024**, *63* (5), 625–631.
- (4) Bresinsky, M.; Shahraki, A.; Kolb, P.; Pockes, S.; Schihada, H. Development of Fluorescent AF64394 Analogues Enables Real-Time Binding Studies for the Orphan Class A GPCR GPR3. *J. Med. Chem.* **2023**, *66*, 15025–15041.
- (5) Tanaka, S.; Ishii, K.; Kasai, K.; Yoon, S. O.; Saeki, Y. Neural Expression of G Protein-Coupled Receptors GPR3, GPR6, and GPR12 Up-Regulates Cyclic AMP Levels and Promotes Neurite Outgrowth*. *J. Biol. Chem.* **2007**, *282* (14), 10506–10515.
- (6) Tanaka, S.; Miyagi, T.; Dohi, E.; Seki, T.; Hide, I.; Sotomaru, Y.; Saeki, Y.; Chiocci, E. A.; Matsumoto, M.; Sakai, N. Developmental Expression of GPR3 in Rodent Cerebellar Granule Neurons Is Associated with Cell Survival and Protects Neurons from Various Apoptotic Stimuli. *Neurobiol. Dis.* **2014**, *68*, 215–227.
- (7) Thathiah, A.; Horr , K.; Snellinx, A.; Vandeweyer, E.; Huang, Y.; Ciesielska, M.; De Kloe, G.; Munck, S.; De Strooper, B. β -Arrestin 2 Regulates A β Generation and γ -Secretase Activity in Alzheimer's Disease. *Nat. Med.* **2013**, *19* (1), 44–49.
- (8) Huang, Y.; Guimar es, T. R.; Todd, N.; Ferguson, C.; Weiss, K. M.; Stauffer, F. R.; McDermott, B.; Hurtle, B. T.; Saito, T.; Saido, T. C.; MacDonald, M. L.; Homanics, G. E.; Thathiah, A. G Protein-Biased GPR3 Signaling Ameliorates Amyloid Pathology in a Preclinical Alzheimer's Disease Mouse Model. *Proc. Natl. Acad. Sci. U.S.A.* **2022**, *119* (40), No. e2204828119, DOI: 10.1073/PNAS.2204828119.
- (9) Thathiah, A.; Spittaels, K.; Hoffmann, M.; Staes, M.; Cohen, A.; Horr , K.; Vanbrabant, M.; Coun, F.; Baekelandt, V.; Delacourte, A.; Fischer, D. F.; Pollet, D.; De Strooper, B.; Merchiers, P. The Orphan G Protein-Coupled Receptor 3 Modulates Amyloid-Beta Peptide Generation in Neurons. *Science* **2009**, *323* (5916), 946–951.
- (10) Huang, Y.; Skwarek-Maruszewska, A.; Horr , K.; Vandeweyer, E.; Wolfs, L.; Snellinx, A.; Saito, T.; Radaelli, E.; Corthout, N.; Colombelli, J.; Lo, A. C.; Van Aerscht, L.; Callaerts-Vegh, Z.; Trabzuni, D.; Bossers, K.; Verhaagen, J.; Ryten, M.; Munck, S.; D'Hooge, R.; Swaab, D. F.; Hardy, J.; Saido, T. C.; De Strooper, B.; Thathiah, A. Loss of GPR3 Reduces the Amyloid Plaque Burden and Improves Memory in Alzheimer's Disease Mouse Models. *Sci. Transl. Med.* **2015**, *7* (309), No. 309ra164.
- (11) Sveidahl Johansen, O.; Ma, T.; Hansen, J. B.; Markussen, L. K.; Schreiber, R.; Reverte-Salisa, L.; Dong, H.; Christensen, D. P.; Sun, W.; Gnad, T.; Karavaeva, I.; Nielsen, T. S.; Kooijman, S.; Cero, C.; Dmytriyeva, O.; Shen, Y.; Razzoli, M.; O'Brien, S. L.; Kuipers, E. N.; Nielsen, C. H.; Orchard, W.; Willemsen, N.; Jespersen, N. Z.; Lundh, M.; Sustarsic, E. G.; Hallgren, C. M.; Frost, M.; McGonigle, S.; Isidor, M. S.; Broholm, C.; Pedersen, O.; Hansen, J. B.; Grarup, N.; Hansen, T.; Kj r, A.; Granneman, J. G.; Babu, M. M.; Calebiro, D.; Nielsen, S.; Ryd n, M.; Soccio, R.; Rensen, P. C. N.; Treebak, J. T.; Schwartz, T. W.; Emanuelli, B.; Bartolomucci, A.; Pfeifer, A.; Zechner, R.; Scheele, C.; Mandrup, S.; Gerhart-Hines, Z. Lipolysis Drives Expression of the Constitutively Active Receptor GPR3 to Induce Adipose Thermogenesis. *Cell* **2021**, *184* (13), 3502–3518.e33.
- (12) Ye, C.; Zhang, Z.; Wang, Z.; Hua, Q.; Zhang, R.; Xie, X. Identification of a Novel Small-Molecule Agonist for Human G Protein-Coupled Receptor 3. *J. Pharmacol. Exp. Ther.* **2014**, *349* (3), 437–443, DOI: 10.1124/jpet.114.213082.
- (13) Laun, A. S.; Song, Z. H. GPR3 and GPR6, Novel Molecular Targets for Cannabidiol. *Biochem. Biophys. Res. Commun.* **2017**, *490* (1), 17–21.
- (14) Wu, J.; Chen, N.; Liu, Y.; Godlewski, G.; Kaplan, H. J.; Shrader, S. H.; Song, Z. H.; Shao, H. Studies of Involvement of G-Protein Coupled Receptor-3 in Cannabidiol Effects on Inflammatory Responses of Mouse Primary Astrocytes and Microglia. *PLoS One* **2021**, *16* (5), No. e0251677, DOI: 10.1371/journal.pone.0251677.
- (15) Yin, H.; Chu, A.; Li, W.; Wang, B.; Shelton, F.; Otero, F.; Nguyen, D. G.; Caldwell, J. S.; Chen, Y. A. Lipid G Protein-Coupled Receptor Ligand Identification Using β -Arrestin PathHunter Assay. *J. Biol. Chem.* **2009**, *284* (18), 12328–12338.
- (16) Uhlenbrock, K.; Gassenhuber, H.; Kostenis, E. Sphingosine 1-Phosphate Is a Ligand of the Human Gpr3, Gpr6 and Gpr12 Family of Constitutively Active G Protein-Coupled Receptors. *Cell. Signal.* **2002**, *14* (11), 941–953.
- (17) Jensen, T.; Elster, L.; Nielsen, S. M.; Poda, S. B.; Loechel, F.; Volbracht, C.; Klewe, I. V.; David, L.; Watson, S. P. The Identification of GPR3 Inverse Agonist AF64394; The First Small Molecule Inhibitor of GPR3 Receptor Function. *Bioorg. Med. Chem. Lett.* **2014**, *24* (22), 5195–5198.
- (18) Ayukawa, K.; Suzuki, C.; Ogasawara, H.; Kinoshita, T.; Furuno, M.; Suzuki, G. Development of a High-Throughput Screening-Compatible Assay for Discovery of GPR3 Inverse Agonists Using a CAMP Biosensor. *SLAS Discovery* **2020**, *25* (3), 287–298.
- (19) Gay, E. A.; Harris, D. L.; Wilson, J. W.; Blough, B. E. The Development of Diphenyleneiodonium Analogs as GPR3 Agonists. *Bioorg. Med. Chem. Lett.* **2023**, *94*, No. 129427.
- (20) Hall, M. P.; Unch, J.; Binkowski, B. F.; Valley, M. P.; Butler, B. L.; Wood, M. G.; Otto, P.; Zimmerman, K.; Vidugiris, G.; MacHleidt, T.; Robers, M. B.; Benink, H. A.; Eggers, C. T.; Slater, M. R.; Meisenheimer, P. L.; Klaubert, D. H.; Fan, F.; Encell, L. P.; Wood, K. V. Engineered Luciferase Reporter from a Deep Sea Shrimp Utilizing a Novel Imidazopyrazinone Substrate. *ACS Chem. Biol.* **2012**, *7* (11), 1848–1857.
- (21) Los, G. V.; Encell, L. P.; McDougall, M. G.; Hartzell, D. D.; Karassina, N.; Zimprich, C.; Wood, M. G.; Learish, R.; Ohana, R. F.; Urh, M.; Simpson, D.; Mendez, J.; Zimmerman, K.; Otto, P.; Vidugiris, G.; Zhu, J.; Darzins, A.; Klaubert, D. H.; Bulleit, R. F.; Wood, K. V. HaloTag: A Novel Protein Labeling Technology for Cell Imaging and Protein Analysis. *ACS Chem. Biol.* **2008**, *3*, 373–382.
- (22) Schihada, H.; Vandenabeele, S.; Zabel, U.; Frank, M.; Lohse, M. J.; Maiellaro, I. A Universal Bioluminescence Resonance Energy Transfer Sensor Design Enables High-Sensitivity Screening of GPCR Activation Dynamics. *Commun. Biol.* **2018**, *1* (1), No. 105, DOI: 10.1038/s42003-018-0072-0.
- (23) Schihada, H.; Nemec, K.; Lohse, M. J.; Maiellaro, I. Bioluminescence in G Protein-Coupled Receptors Drug Screening Using Nanoluciferase and Halo-Tag Technology. *Methods Mol. Biol.* **2021**, *2268*, 137–147.

(24) Schihada, H.; Ma, X.; Zabel, U.; Vischer, H. F.; Schulte, G.; Leurs, R.; Pockes, S.; Lohse, M. J. Development of a Conformational Histamine H3 Receptor Biosensor for the Synchronous Screening of Agonists and Inverse Agonists. *ACS Sens.* **2020**, *5* (6), 1734–1742.

(25) Zhang, J. H.; Chung, T. D. Y.; Oldenburg, K. R. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. *SLAS Discovery* **1999**, *4* (2), 67–73.

(26) Crousillac, S.; Colonna, J.; McMains, E.; Dewey, J. S.; Gleason, E. Sphingosine-1-Phosphate Elicits Receptor-Dependent Calcium Signaling in Retinal Amacrine Cells. *J. Neurophysiol.* **2009**, *102* (6), 3295–3309.

(27) Kolb, P.; Ferreira, R. S.; Irwin, J. J.; Shoichet, B. K. Docking and Chemoinformatic Screens for New Ligands and Targets. *Curr. Opin. Biotechnol.* **2009**, *20* (4), 429–436.

(28) Backman, T. W. H.; Cao, Y.; Girke, T. ChemMine Tools: An Online Service for Analyzing and Clustering Small Molecules. *Nucleic Acids Res.* **2011**, *39* (2), W486–W491, DOI: 10.1093/NAR/GKR320.

(29) Schihada, H.; Shekhani, R.; Schulte, G. Quantitative Assessment of Constitutive G Protein–Coupled Receptor Activity with BRET-Based G Protein Biosensors. *Sci. Signal.* **2021**, *14* (699), No. eabf1653.

(30) Klarenbeek, J.; Goedhart, J.; Van Batenburg, A.; Groenewald, D.; Jalink, K. Fourth-Generation Epac-Based FRET Sensors for CAMP Feature Exceptional Brightness, Photostability and Dynamic Range: Characterization of Dedicated Sensors for FLIM, for Ratiometry and with High Affinity. *PLoS One* **2015**, *10*, No. e0122513, DOI: 10.1371/journal.pone.0122513.

(31) Chen, G.; Bláhová, J.; Staffen, N.; Hübner, H.; Nunhöfer, N.; Qiu, C.; Gmeiner, P.; Weikert, D.; Du, Y.; Xu, J. Mechanism and Function of GPR3 Regulated by a Negative Allosteric Modulator. *Nat. Commun.* **2025**, *16* (1), No. 7988.

(32) Barekatin, M.; Johansson, L. C.; Lam, J. H.; Chang, H.; Sadybekov, A. V.; Han, G. W.; Russo, J.; Bliesath, J.; Brice, N. L.; Carlton, M. B. L.; Saikatendu, K. S.; Sun, H.; Murphy, S. T.; Monenschein, H.; Schiffer, H. H.; Popov, P.; Lutowski, C. A.; Robinson, C. V.; Liu, Z. J.; Hua, T.; Katritch, V.; Cherezov, V. Structural Insights into the High Basal Activity and Inverse Agonism of the Orphan Receptor GPR6 Implicated in Parkinson's Disease. *Sci. Signal.* **2024**, *17* (865), No. eado8741, DOI: 10.1126/scisignal.a-do8741.

(33) Daina, A.; Michielin, O.; Zoete, V. SwissADME: A Free Web Tool to Evaluate Pharmacokinetics, Drug-Likeness and Medicinal Chemistry Friendliness of Small Molecules. *Sci. Rep.* **2017**, *7* (1), No. 42717.



CAS BIOFINDER DISCOVERY PLATFORM™

PRECISION DATA FOR FASTER DRUG DISCOVERY

CAS BioFinder helps you identify
targets, biomarkers, and pathways

Unlock insights

CAS
A Division of the
American Chemical Society